Whole Genome Sampling Identifies Targetable Prostate Cancer Subgoups

Audio Journal of Oncology Podcast

CHICAGO—Clinically targetable mutations were identified and patient subgroups pinpointed by whole genome sampling (WGS) of castration-resistant metastatic prostate cancer (mPC) in a study reportedatthe 2018 Annual Meeting of the American Society of Clinical Oncology. (https://meetinglibrary.asco.org/record/160671/abstract)

Lisanne F van Dessel MD, a medical oncologist at Erasmus Medical Center Cancer Institute in Rotterdam, The Netherlands, tells the Audio Journal of Onclogy that while their research confirmed that this disease was complex and unstable they had found potentially actionable targets waiting to be studied for therapeutic use which were also likely to be prognostic, predictive or both.